Jason A. Leverone - 22 Jun 2026 Form 4 Insider Report for OnKure Therapeutics, Inc. (OKUR)

Reporting relationship: Chief Financial Officer
Issuer ticker: OKUR
Reported as of: 22 Jun 2026
Net transaction value: -$1,332
SEC form: 4
Accepted by SEC: 24 Jun 2026, 19:27:44 UTC
Prior SEC filing: 03 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Rogan Nunn, by power of attorney

Key filing fact

Jason A. Leverone filed Form 4 for OnKure Therapeutics, Inc. (OKUR) on 24 Jun 2026.

Key facts

This page summarizes Jason A. Leverone's Form 4 filing for OnKure Therapeutics, Inc. (OKUR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Jun 2026, 19:27.

Change

Previous filing in this sequence was filed on 03 Apr 2026.
Current net transaction value: -$1,332.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001692747 Primary reporting owner

Leverone Jason A.

Relationship: Chief Financial Officer
Address: C/O ONKURE THEREAPEUTICS, INC., 6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Signature: /s/ Rogan Nunn, by power of attorney
Signature date: 24 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OKUR transaction

Class A Common Stock

Sale

Transaction value: $1,332
Shares: -303
Change %: -1.6%
Price: $4.40
Shares after: 18,802
Date: 22 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $4.27 to $4.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F3

Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Footnote F4

Includes 3,105 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on May 20, 2026.